<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03155945</url>
  </required_header>
  <id_info>
    <org_study_id>APD371-004</org_study_id>
    <nct_id>NCT03155945</nct_id>
  </id_info>
  <brief_title>Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain</brief_title>
  <official_title>A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, open-label, parallel, phase 2a study is to determine the&#xD;
      tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease&#xD;
      experiencing abdominal pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to approximately 12 weeks</time_frame>
    <description>TEAE was defined as an adverse event (AE) that occurred after first dose of olorinab. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events. Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Exploratory - Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Olorinab and Its Metabolites at Week 8</measure>
    <time_frame>Week 8: Pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Median Time for Cmax (Tmax) of Olorinab and Its Metabolites at Week 8</measure>
    <time_frame>Week 8: Pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Mean Area Under the Concentration Time Curve From Time of Dosing to 8 Hours Post-dose (AUC0-8) of Olorinab and Its Metabolites at Week 8</measure>
    <time_frame>Week 0 (Day 1, Day 2), Week 8 (Day -1), Week 8: Pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Mean Change in Abdominal Pain Score (APS) From Trough to Peak at Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Change From Baseline in Average APS (AAPS)</measure>
    <time_frame>Baseline; Week 1, 2, 4, 6 and 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Number of Participants Who Were End-of-treatment Responders</measure>
    <time_frame>Week 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Number of Participants Who Were Weekly Responders</measure>
    <time_frame>Weeks 1, 2, 4, 6, and 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Number of Pain-free Days Per Week</measure>
    <time_frame>Week 1, Week 2, Week 4, Week 6, Week 8, and end of treatment</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Number of Participants Who Used Pain Rescue Medication</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Change From Baseline in C-reactive Protein (CRP) Levels at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Change From Baseline in Fecal Calprotectin Levels at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>The result for this exploratory endpoint was not reported.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>Olorinab 25 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olorinab 100 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received olorinab 100 mg oral tablets TID for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olorinab</intervention_name>
    <description>Olorinab active treatment for 8 weeks.</description>
    <arm_group_label>Olorinab 100 mg TID</arm_group_label>
    <arm_group_label>Olorinab 25 mg TID</arm_group_label>
    <other_name>APD371</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of Crohn's disease for at least 3 months prior to screening&#xD;
             corroborated by prior endoscopic and histopathologic documentation consistent with&#xD;
             Crohn's disease.&#xD;
&#xD;
          -  Quiescent to mildly active inflammatory Crohn's disease defined with a total of simple&#xD;
             endoscopy score for Crohn's disease (SES-CD) score of &lt; 10 or fecal calprotectin &lt; 500&#xD;
             mcg/g within 4 weeks before Screening.&#xD;
&#xD;
          -  Moderate to severe abdominal pain as defined by average abdominal pain score (AAPS) of&#xD;
             &gt;/= 4points on 7 consecutive days of the screening period up to Day -2. AAPS will be&#xD;
             based on the 11-point numeric rating scale where 0 (no abdominal pain) to 10 (worst&#xD;
             possible abdominal pain).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Female participants who are lactating or have a positive serum pregnancy test during&#xD;
             the screening period or a positive urine pregnancy test on Day 1 prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Recent history (within 6 months of screening visit) of cerebrovascular disease, Acute&#xD;
             Coronary Syndrome, Cerebrovascular accident, Transient ischemic attack, Myocardial&#xD;
             infarction, unstable angina.&#xD;
&#xD;
          -  Other significant chronic pain conditions that in the opinion of the Investigator may&#xD;
             influence the abdominal pain score.&#xD;
&#xD;
          -  History of extensive colonic resection, subtotal or total colectomy.&#xD;
&#xD;
          -  History of &gt;3 small bowel resections or diagnosis of short bowel syndrome or who have&#xD;
             undergone bowel resection within 6 months prior to randomization.&#xD;
&#xD;
          -  Chronic active hepatitis B within the last year (unless shown at the time of study&#xD;
             entry to be hepatitis B antigen negative) or any history of hepatitis C.&#xD;
&#xD;
          -  Evidence of current gastro-intestinal infection (bacterial or parasitic) or&#xD;
             significant infection within 45 days of screening.&#xD;
&#xD;
        Note: other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arena CT.gov Administrator</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research of Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://academic.oup.com/crohnscolitis360/article/3/1/otaa089/5937224</url>
    <description>Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <results_first_submitted>September 3, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <disposition_first_submitted>September 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 5, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 2, 2021</disposition_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03155945/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03155945/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 37 participants were screened for the study. Of these, 23 participants failed screening, and 14 participants were randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olorinab 25 mg TID</title>
          <description>Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Olorinab 100 mg TID</title>
          <description>Participants received olorinab 100 mg tablet by mouth, TID for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: All randomized participants who received at least 1 dose of olorinab.</population>
      <group_list>
        <group group_id="B1">
          <title>Olorinab 25 mg TID</title>
          <description>Participants received olorinab 25 mg tablet by mouth, TID for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Olorinab 100 mg TID</title>
          <description>Participants received olorinab 100 mg tablet by mouth, TID for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="10.81"/>
                    <measurement group_id="B2" value="36.9" spread="15.20"/>
                    <measurement group_id="B3" value="36.1" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>TEAE was defined as an adverse event (AE) that occurred after first dose of olorinab. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events. Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.</description>
        <time_frame>Up to approximately 12 weeks</time_frame>
        <population>Safety Population: All randomized participants who received at least 1 dose of olorinab.</population>
        <group_list>
          <group group_id="O1">
            <title>Olorinab 25 mg TID</title>
            <description>Participants received olorinab 25 mg tablet by mouth, TID for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olorinab 100 mg TID</title>
            <description>Participants received olorinab 100 mg tablet by mouth, TID for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <description>TEAE was defined as an adverse event (AE) that occurred after first dose of olorinab. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events. Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.</description>
          <population>Safety Population: All randomized participants who received at least 1 dose of olorinab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Olorinab and Its Metabolites at Week 8</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Week 8: Pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Median Time for Cmax (Tmax) of Olorinab and Its Metabolites at Week 8</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Week 8: Pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Mean Area Under the Concentration Time Curve From Time of Dosing to 8 Hours Post-dose (AUC0-8) of Olorinab and Its Metabolites at Week 8</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Week 0 (Day 1, Day 2), Week 8 (Day -1), Week 8: Pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Mean Change in Abdominal Pain Score (APS) From Trough to Peak at Week 8</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Baseline; Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Change From Baseline in Average APS (AAPS)</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Baseline; Week 1, 2, 4, 6 and 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Number of Participants Who Were End-of-treatment Responders</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Number of Participants Who Were Weekly Responders</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Weeks 1, 2, 4, 6, and 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Number of Pain-free Days Per Week</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Week 1, Week 2, Week 4, Week 6, Week 8, and end of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Number of Participants Who Used Pain Rescue Medication</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Up to Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Change From Baseline in C-reactive Protein (CRP) Levels at Week 4 and Week 8</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory - Change From Baseline in Fecal Calprotectin Levels at Week 4 and Week 8</title>
        <description>The result for this exploratory endpoint was not reported.</description>
        <time_frame>Baseline, Week 4, Week 8</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 12 weeks</time_frame>
      <desc>TEAE was defined as an adverse event (AE) that occurred after first dose of olorinab. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olorinab 25 mg TID</title>
          <description>Participants received olorinab 25 milligrams (mg) oral tablets three times daily (TID) for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Olorinab 100 mg TID</title>
          <description>Participants received olorinab 100 mg oral tablets TID for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Acute interstitial pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDra 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>C-reactive protein decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arena CT.gov Administrator</name_or_title>
      <organization>Arena Pharmaceuticals, Inc.</organization>
      <phone>+1 855-218-9153</phone>
      <email>ct.gov@arenapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

